Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dicerna Pharmaceuticals, Inc.

http://www.dicerna.com

Latest From Dicerna Pharmaceuticals, Inc.

China mRNA Player Abogen Gets $300m More As Country Eyes Omicron Threat

From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.

China Coronavirus COVID-19

Arrowhead Gets $120m From GSK For First-In-Class NASH RNAi Candidate

GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.

Deals Business Strategies

RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna

The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.

M & A Business Strategies

Assembly Looks To Quickly Move Past ABI-H2158 Discontinuation

The company’s triple-combination studies with vebicorvir and next-generation core inhibitor programs may hold more promise in hepatitis B.

Clinical Trials Drug Safety
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
UsernamePublicRestriction

Register